Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Next Previous
Trial Profile

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; Tivumecirnon (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Lymphoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE-877
  • Sponsors RAPT Therapeutics

    • Most Recent Events

    • 09 Apr 2024 According to a RAPT Therapeutics media release, company today announced safety and efficacy data from its ongoing Phase 2 trial and presented this data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
    • 09 Apr 2024 Results published in a RAPT Therapeutics media release
    • 01 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Jan 2025.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top